Harrow, Inc. is rapidly evolving into a dominant US ophthalmic pharma player, with a 30-fold revenue increase since 2015 and strong operating leverage. Read more macro analysis here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results